Polarean Imaging PLC (LON:POLX) is showcasing its technological advances in magnetic resonance imaging at two virtual industry conferences.
Researchers assessed the use of the drug-device combination to assist with the early diagnosis of respiratory diseases, while they were also interested in the ability to monitor progression and therapeutic response in the patients.
“Many of the projects being presented at these two leading conferences have made use of Polarean's products to conduct research, highlighting the growing academic acceptance of the company's technology,” Polarean chief executive Richard Hullihen said in a statement.
“We hope that the inclusion of so many sessions on 129Xenon will continue to showcase Polarean's important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system."